Callum M Sloss
Overview
Explore the profile of Callum M Sloss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deutschman E, Fulton R, Sloss C
Arch Pathol Lab Med
. 2025 Mar;
PMID: 40073910
Context.—: The VENTANA FOLR1 (FOLR1-2.1) RxDx (FOLR1 CDx) assay, developed by Roche Tissue Diagnostics, is a Food and Drug Administration-approved immunohistochemical assay intended for use in the assessment of folate...
2.
Tu Y, Lagraauw H, Method M, Wang Y, Hanze E, Li L, et al.
Br J Clin Pharmacol
. 2024 Sep;
91(1):220-231.
PMID: 39307840
Aims: This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the treatment of folate receptor-α-positive...
3.
Daver N, Montesinos P, DeAngelo D, Wang E, Papadantonakis N, Todisco E, et al.
Lancet Oncol
. 2024 Feb;
25(3):388-399.
PMID: 38423051
Background: Pivekimab sunirine (IMGN632) is a first-in-class antibody-drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute...
4.
James R, Sisserson T, Cai Z, Dumas M, Inge L, Ranger-Moore J, et al.
Arch Pathol Lab Med
. 2024 Jan;
148(11):1226-1233.
PMID: 38282564
Context.—: Folate receptor-α (FRα, encoded by the FOLR1 gene) is overexpressed in several solid tumor types, including epithelial ovarian cancer (EOC), making it an attractive biomarker and target for FRα-based...
5.
Tu Y, Hanze E, Zhu F, Lagraauw H, Sloss C, Method M, et al.
Br J Clin Pharmacol
. 2023 Oct;
90(2):568-581.
PMID: 37872122
Aims: Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate recently approved for the treatment of folate receptor-α positive ovarian cancer. The aim of this study was to develop a population pharmacokinetic...
6.
Hicks S, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas A, et al.
Haematologica
. 2019 Feb;
104(8):1633-1639.
PMID: 30733273
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development....
7.
Kovtun Y, Noordhuis P, Whiteman K, Watkins K, Jones G, Harvey L, et al.
Mol Cancer Ther
. 2018 Mar;
17(6):1271-1279.
PMID: 29588393
The myeloid differentiation antigen CD33 has long been exploited as a target for antibody-based therapeutic approaches in acute myeloid leukemia (AML). Validation of this strategy was provided with the approval...
8.
Hicks S, Lai K, Gavrilescu L, Yi Y, Sikka S, Shah P, et al.
Neoplasia
. 2017 Jul;
19(9):661-671.
PMID: 28753442
Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin...
9.
Kearns J, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner S, et al.
Mol Cancer Ther
. 2015 Apr;
14(7):1625-36.
PMID: 25911688
Although EGFR is a validated therapeutic target across multiple cancer indications, the often modest clinical responses to current anti-EGFR agents suggest the need for improved therapeutics. Here, we demonstrate that...
10.
Al-Mutairi M, Cadalbert L, McGachy H, Shweash M, Schroeder J, Kurnik M, et al.
PLoS Pathog
. 2010 Nov;
6(11):e1001192.
PMID: 21085614
In this study we generated a novel dual specific phosphatase 4 (DUSP4) deletion mouse using a targeted deletion strategy in order to examine the role of MAP kinase phosphatase-2 (MKP-2)...